Cerevel Therapeutics Holdings announced that it has commenced an underwritten public offering of $400M of shares of its common stock. Goldman Sachs & Co. is acting as the lead book-running manager for the offering. Stifel, Nicolaus & Company is also acting as a book-running manager for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CERE:
- Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
- Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
- Cerevel initiated with Overweight on blockbuster potential at Piper
- Cerevel Therapeutics initiated with an Overweight at Piper Sandler
- Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference